<DOC>
	<DOCNO>NCT00400660</DOCNO>
	<brief_summary>GSK615915A develop novel surfactant use formulation GSK 's future generation Metered Dose Inhalers ( MDIs ) . A surfactant MDI would provide stable drug suspension , turn produce consistent dose drug deliver puff .</brief_summary>
	<brief_title>A First Time In Human Study To Assess The Compound GSK615915</brief_title>
	<detailed_description />
	<mesh_term>Bronchial Spasm</mesh_term>
	<criteria>Women nonchild bear potential . Body weight = 50 kg ( 110 lb ) men = 45 kg woman Body Mass Index ( BMI ) within range 19.030.0 kg/m² The subject current nonsmoker use tobacco product last 12 month pack history = 10 pack year . The subject demonstrate ability correctly use meter dose inhaler device . If asthmatic : The subject must clinically stable The subject baseline FEV1 = 80 % predict . As result medical interview , physical examination screen investigation , Physician Responsible considers volunteer unfit study . The subject history allergy excipients , MDI propellant , history drug allergy , opinion physician responsible make volunteer unfit participate . The subject recently participate another clinical trial . The subject use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St Johnâ€™s Wort ) within 7 14 day . The subject average weekly alcohol intake great 21 unit male 14 unit female , average daily intake great 3 unit regularly , 1 unit equivalent halfpint ( 220mL ) beer 1 ( 25ml ) measure spirit 1 glass ( 125ml ) wine . Any history breathing problem ( e.g . history asthmatic symptom ) . The subject infect hepatitis B , hepatitis C , HIV virus . The subject positive drug abuse test . The subject respiratory tract infection within 4 week start study . The subject past present disease , judge Doctor , may affect outcome study . The subject history lifethreatening asthma . The subject take inhaled , nasal dermal steroid within 4 week oral steroid within 8 week start study . The subject take long act inhale beta 2 agonist within 96 hour screen visit . The subject take short act inhaled beta 2 agonist within 8 hour screen visit . The subject unable abstain drug may interfere conduct study interpretation . The subject ongoing rhinitis require treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>GSK615915 asthma surfactant MDI</keyword>
</DOC>